AstraZeneca has announced a commitment to invest $15 billion in its China operations by 2030. The company stated that this funding will be used to expand its work in cell therapies and radioconjugates, with the goal of developing new treatments for cancer, autoimmune diseases, and other conditions. According to AstraZeneca, the investment will support all phases of drug development, from initial design through clinical trials and manufacturing.
The company also said that the new investment would help “bring Chinese innovation to the world.” AstraZeneca plans to further develop its production facilities in Wuxi, Taizhou, and Beijing. These plants supply medicines both locally and to 70 international markets.
AstraZeneca has been increasing its investments in China over recent years. Last week, it paid $630 million to acquire full rights to a cancer cell therapy developed with Shanghai’s AbelZeta, building on an alliance that began in late 2023.
In March 2025, AstraZeneca announced several deals that could bring over $10 billion of investment into China. This included a $2.5 billion plan for a sixth global R&D center in Beijing and a global antibody partnership with Harbour BioMed worth more than $4.5 billion. In June 2025, AstraZeneca agreed to pay up to $5.3 billion in collaboration with CSPC Pharmaceutical to use their AI-driven technology for immunological diseases. By the end of the year, the company pledged another potential $2 billion contract with Jacobio Pharma for an early-stage pan-KRAS blocker.
“These investments will significantly enhance our capabilities in cell therapies and radioconjugates,” AstraZeneca said in its Thursday news release.
The company’s ongoing expansion reflects broader trends as biopharma companies continue increasing their financial commitments within China.
